MEDP News

This week’s three IPOs raised a combined $263 million. Continuing a streak of outperformance from larger IPOs, contract research organization Medpace led with a 21% gain, while Protagonist Therapeutics was the latest biotech IPO to break issue. Currently in the middle of its annual summer hiatus, the IPO market saw no new filings or launches this week. Since the IPO...read more

Medpace Holdings, a global full-service CRO focused on small and mid-sized biopharmaceuticals, raised $161 million by offering 7 million shares at $23, the high end of the range of $20 to $23. Medpace Holdings plans to list on the Nasdaq under the symbol MEDP. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as lead managers on the deal....read more

Four companies are set to raise a combined $270 million in the week ahead. Most notable deal Medpace, a contract research organization focused on biotechs, is joined by two potential customers: Protagonist Therapeutics and Motif Bio. Thanks to insider support, biotechs are the most active segment of the 2016 IPO market, with 20 offerings year-to-date (36% of total), but their...read more

inVentiv Group Holdings, one of the largest global contract research organizations, withdrew its plans for an initial public offering on Wednesday. It originally filed in April 2016 with an estimated deal size of $500 million. inVentiv withdrew after Advent International, a global private equity firm, took a significant stake in the company. Competing CRO Medpace (MEDP),...read more